BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35404996)

  • 21. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
    Li J; Stagg NJ; Johnston J; Harris MJ; Menzies SA; DiCara D; Clark V; Hristopoulos M; Cook R; Slaga D; Nakamura R; McCarty L; Sukumaran S; Luis E; Ye Z; Wu TD; Sumiyoshi T; Danilenko D; Lee GY; Totpal K; Ellerman D; Hötzel I; James JR; Junttila TT
    Cancer Cell; 2017 Mar; 31(3):383-395. PubMed ID: 28262555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
    Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
    Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
    Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
    Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.
    Peng F; Wang Y; Zhao J; Liu H; Liu Z; Ding K; Zhang H; Fu R
    Br J Haematol; 2023 May; 201(3):417-421. PubMed ID: 35594370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma.
    Kodama T; Kochi Y; Nakai W; Mizuno H; Baba T; Habu K; Sawada N; Tsunoda H; Shima T; Miyawaki K; Kikushige Y; Mori Y; Miyamoto T; Maeda T; Akashi K
    Mol Cancer Ther; 2019 Sep; 18(9):1555-1564. PubMed ID: 31270154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
    Moore DC; Granger K; Hill H; Karabinos A; Davis JA
    Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
    [No Abstract]   [Full Text] [Related]  

  • 31. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
    Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
    Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quad-class exposed/refractory myeloma is associated with short survival.
    Piron B; Costes-Tertrais D; Gastinne T; Fourmont AM; Dubruille V; Blin N; Moreau P; Touzeau C; Tessoulin B
    Br J Haematol; 2024 Jan; 204(1):186-190. PubMed ID: 37833834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
    Tanenbaum B; Miett T; Patel SA
    Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
    Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
    Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
    Hönemann D; Kufer P; Rimpler MM; Chatterjee M; Friedl S; Riecher F; Bommert K; Dörken B; Bargou RC
    Leukemia; 2004 Mar; 18(3):636-44. PubMed ID: 14737072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
    Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
    PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
    Braunstein M; Weltz J; Davies F
    Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
    Parrondo RD; Ailawadhi S; Cerchione C
    Front Oncol; 2024; 14():1394048. PubMed ID: 38660139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
    Mutlu YG; Yıgıt Kaya S; Maral S; Melek E; Baslar Z; Kaynar L; Sevindik OG
    Front Immunol; 2023; 14():1276295. PubMed ID: 37901215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.